Idorsia receives US FDA approval of QUVIVIQ (daridorexant)
25 and 50 mg for the treatment of adults with insomnia
"Idorsia is committed to build our US affiliate to meet the changing needs of healthcare professionals, patients and their families."
Patty Torr
Meet us on social media and join the conversation!
Idorsia US was established to ensure that patients can benefit from the company’s pioneering therapies.
Idorsia's development compounds target a number of different diseases.
Stay up to date on the latest news from Idorsia US.
For more information and news about Idorsia Pharmaceuticals Ltd please visit our global corporate website.
